COMP <GO>
NUTX vs RSKD // RETURN ON INVESTED CAPITAL (ROIC)
Nutex Health Inc. (NASDAQ) VS. Riskified Ltd. (Class A) (NYSE) • 15-METRIC TALLY: NUTX 7
— RSKD 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: NUTX
LAST: $210.10 (-1.19%) • MKT CAP: $1.44B
roic
85.00%
LAST: $8.99 (-0.55%) • MKT CAP: $1.22B
roic
-20.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUTX VS. RSKD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUTX | RSKD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.80% | 51.70% | -0.90 | RSKD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 85.00% | -20.30% | +105.30 | NUTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 17.07% | 2.71% | +14.36 | NUTX | /fcf-yield <GO> |
| Operating Margin | 31.50% | -9.90% | +41.40 | NUTX | /operating-margins <GO> |
| Net Profit Margin | 8.10% | -8.00% | +16.10 | NUTX | /net-margins <GO> |
| Revenue Growth (YoY) | 82.40% | 5.20% | +77.20 | NUTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.75 | 6.12 | -2.37 | RSKD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | NUTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 55.6 | -8.89 | RSKD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.1x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $1.22B | $216.4M | NUTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUTX REV | RSKD REV | NUTX GROSS % | RSKD GROSS % | NUTX FCF | RSKD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $875.3M | $344.6M | 50.8% | 51.7% | $245.6M | $33.1M |
| FY 2024 | $479.9M | $327.5M | 40.9% | 52.2% | $20.8M | $39.1M |
| FY 2023 | $247.6M | $297.6M | — | — | $1.3M | $7.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUTX // BETA —
RSKD // BETA —